ShanghaiBio announced the appointment of Michael Lutz as its advisor for ongoing global corporate development activities. Lutz was formerly senior VP of pharmacogenetics partnerships for Clinical Data's PGxHealth division and global general manager of the company's Cogenics division.
Pathway Genomics has appointed Sidney Stolz as its new chief growth officer, responsible for expanding Pathway's direct-to-consumer genetic testing services.
Before coming to Pathway, Stolz was executive VP of Healthcare Solutions. He has also held various executive positions at Towers Perrin and UnitedHealth Group. In 1997, Stolz became the CEO of UHG's global consulting division.
Exagen Diagnostics announced the appointment of Scott Glenn as its new CEO and chairman of its board of directors. Glenn replaces interim CEO Waneta Tuttle.
Prior to joining Exagen, Glenn was managing partner of Windamere Venture Partners and founded several biomedical companies, including Prometheus Laboratories, Santarus, Dexcom, among others. Before joining Windamere Ventures, Glenn was president and CEO of Quidel and held various positions with Allergan Pharmaceuticals.